Fremanezumab reduces number of migraine days in children, teens

Fremanezumab yields a greater reduction in the number of migraine days and headache days than placebo among children and adolescents with episodic migraine, according to a study published in the Jan. 15 issue of the New England Journal of Medicine.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup